---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-019573"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:25:44.244142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M

## Summary
- Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.
- Cash $144.4M + $180M PRV proceeds extend runway into Q2 2028.
- FDA granted accelerated approval for KRESLADI in severe LAD-I in March 2026.
- Monetized Rare Pediatric Disease PRV for $180M on April 28, 2026.
- Pivotal Phase 2 trial of RP-A501 for Danon disease dosing reinitiated; RP-A701 first dosing expected mid-2026.

## SEC filing metadata
- accession: 0001140361-26-019573
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/0001140361-26-019573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/ef20072739_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-019573
- JSON: https://secwatch.observer/filing/0001140361-26-019573.json
- Plain text: https://secwatch.observer/filing/0001140361-26-019573.txt

## Source-grounded claims
- claim_id: 6386b71c10ad11b5c93dbaac2825ce5e71ac5209
  claim: ROCKET PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: net income Net loss was $47.6 million or $0.42 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.42 per share (basic and diluted).
  evidence_excerpt: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/0001140361-26-019573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.